These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Glucose tolerance status and 20 year cancer incidence.
    Author: Dankner R, Chetrit A, Segal P.
    Journal: Isr Med Assoc J; 2007 Aug; 9(8):592-6. PubMed ID: 17877065.
    Abstract:
    BACKGROUND: Type 2 diabetes, an extreme state of glucose intolerance, has been found to be associated with cancer mortality; less is known about impaired glucose tolerance and cancer incidence. OBJECTIVES: To examine the association between fasting and post-load plasma glucose and insulin, and the 20 year incidence of cancer. METHODS: We followed a sample of the Jewish Israeli population (n = 2780), free of cancer at baseline, from 1977-1980 to 1999 for cancer incidence and mortality. Baseline fasting and 1 and 2 hour post-load plasma glucose levels were recorded, as was insulin, in 1797 of them. RESULTS: During 20 years, 329 individuals (11.8%) developed cancer. Cancer incidence for all sites differed between men and women (13.0% and 10.7%, P = 0.03), and among different glucose tolerance status groups (P = 0.01). Cancer incidence hazard ratio, by glucose status adjusted for gender, age, ethnicity, smoking and body mass index, was 1.24 (95% CI 0.96-1.62, P = 0.10) for impaired fasting glucose or impaired glucose tolerance, and 1.32 (95% CI 0.96-1.81, P = 0.09) for type 2 diabetes mellitus, compared with those who were normoglycemic at baseline. Fasting insulin and cancer incidence were not associated. CONCLUSIONS: An increased long-term cancer risk for individuals with impaired fasting glucose or glucose tolerance, or diabetes, is suggested. Even this modest association could have substantial public health consequences.
    [Abstract] [Full Text] [Related] [New Search]